Bridging the gap between medical advances and clinical practices

(Photo courtesy of PIxabay).

Research and innovation in genomic medicine are surging. However, the adoption of new research into clinical practice has been comparatively slow. A new Des Moines-based company is looking to change that.

Since opening his own medical consulting firm in 2004, Jake Velie has worked with physician groups, insurance carriers and large companies from around the world.

“Most of my consulting was in the value-based medical world where health systems and practices are trying to figure out new ways and workflows to improve patient outcomes without any additional tools like medicines and surgeries.” Velie said. “And I didn’t realize it at the time, but that was actually the very forefront of what was going on in medicine.”

In 2013, Velie began to shift his focus from working with directly with patients and physicians on the ground to working with larger populations. He began working with large self-funded groups from all over the country and develop clinical strategies and risk management for them.

“Once I got into that, I immediately started to run into really innovative clinical services and products providers, companies that were doing some really amazing things,” Velie said. “There was such a divide between the technology that was available on the genetic side and actual application. People weren’t getting these tools that are readily available.”

So in 2017, Velie spun a new company, Rx-Precision, out of his consulting  firm. Rx-Precision is a risk case management firm focused on providing clients solutions for integration of pharmacogenomics and precision medicine to reduce risk and lower costs in high genomic-risk populations.

The company recently completed beta testing and now is preparing to launch several different pilot initiatives through commercial insurers and self-funded employers in 2019. 

“Most health insurance companies don’t pay for genomic testing and most physicians don’t use genomic testing in practice,” Velie said. “Not because there’s not enough science behind it, but because physicians haven’t been trained in it.”

Velie says he expects the company to be working on pilots for the next two years.